Data suggests that other factors also contribute to cytotoxicity. The α t1/2 is 1.1 to 2 hours and the β t1/2 is 2.6 to 5.9 hours. Carboplatin is not protein bound. The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. In patients with creatinine clearances below 60 mL/min the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. Carboplatin dosages will require adjustment dependent on the glomerular filtration rate. Formulation and Stability Carboplatin is available in 50 mg, 150 mg, 450 mg and 600 mg vials. Aqueous Solution: Carboplatin aqueous solution is supplied as a sterile, pyrogenfree, 10mg/mL aqueous solution of carboplatin in multidose vials. Unopened vials of carboplatin aqueous solution are stable to the date indicated on the package when stored at 25° C (77° F); excursions permitted from 15°- 30° C (59°- 86° F). Protect from light. Carboplatin aqueous solution multidose vials maintain microbial, chemical, and physical stability for up to 14 days at 25º C following multiple needle entries. Powder for Injection: Carboplatin powder for i njection is a sterile lyophilized white powder in single dose vials containing equal parts by weight of carboplatin and mannitol. Unopened vials of carboplatin are stable to the date indicated on the package when stored at 15° -30° C (59°- 86° F). Protect fr om light.